Total Payments
$153,154
2024 Payments
$15,180
Companies
11
Transactions
37
Payment Breakdown by Category
Research$146,855 (95.9%)
Consulting$5,843 (3.8%)
Food & Beverage$455.75 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $146,855 | 6 | 95.9% |
| Consulting Fee | $5,843 | 9 | 3.8% |
| Food and Beverage | $455.75 | 22 | 0.3% |
Payments by Type
Research
$146,855
6 transactions
General
$6,299
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $146,959 | 12 | $0 (2024) |
| Global Blood Therapeutics, Inc. | $4,256 | 2 | $0 (2021) |
| Helena Laboratories Corporation | $1,125 | 6 | $0 (2017) |
| VERTEX PHARMACEUTICALS INCORPORATED | $483.33 | 2 | $0 (2020) |
| Amgen Inc. | $180.92 | 7 | $0 (2020) |
| Celgene Corporation | $64.86 | 3 | $0 (2020) |
| Spectrum Pharmaceuticals Inc. | $22.05 | 1 | $0 (2019) |
| Incyte Corporation | $20.32 | 1 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $14.85 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $14.21 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,180 | 1 | Novartis Pharmaceuticals Corporation ($15,180) |
| 2023 | $44,190 | 2 | Novartis Pharmaceuticals Corporation ($44,190) |
| 2022 | $69,510 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($69,510) |
| 2021 | $20,711 | 3 | Novartis Pharmaceuticals Corporation ($16,455) |
| 2020 | $2,129 | 9 | Novartis Pharmaceuticals Corporation ($1,549) |
| 2019 | $194.73 | 9 | Amgen Inc. ($75.90) |
| 2018 | $95.85 | 5 | Amgen Inc. ($50.83) |
| 2017 | $1,144 | 7 | Helena Laboratories Corporation ($1,125) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/02/2024 | Novartis Pharmaceuticals Corporation | ADAKVEO (Drug) | — | Cash or cash equivalent | $15,180.00 | Research |
| Study: A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises • Category: Hematology | ||||||
| 11/08/2023 | Novartis Pharmaceuticals Corporation | ADAKVEO (Drug) | — | Cash or cash equivalent | $11,760.00 | Research |
| Study: A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises • Category: Hematology | ||||||
| 01/04/2023 | Novartis Pharmaceuticals Corporation | ADAKVEO (Drug) | — | Cash or cash equivalent | $32,430.00 | Research |
| Study: A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises • Category: Hematology | ||||||
| 01/07/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | ADAKVEO (Biological) | — | Cash or cash equivalent | $69,510.00 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PAT • Category: HEMATOLOGY | ||||||
| 08/18/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,235.00 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 08/18/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | Cash or cash equivalent | $20.98 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 05/25/2021 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | — | Cash or cash equivalent | $16,455.00 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PATIENTS WITH VASO-OCCLUSIVE CRISES • Category: HEMATOLOGY | ||||||
| 12/01/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $237.50 | General |
| 11/24/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $245.83 | General |
| 10/09/2020 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | — | Cash or cash equivalent | $1,520.00 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PAT • Category: HEMATOLOGY | ||||||
| 03/05/2020 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: HEMATOLOGY | ||||||
| 02/13/2020 | Celgene Corporation | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $22.00 | General |
| Category: Hematology | ||||||
| 02/06/2020 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.32 | General |
| Category: Hematology/Oncology | ||||||
| 01/30/2020 | Amgen Inc. | Nplate (Biological) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Hematology | ||||||
| 01/16/2020 | Amgen Inc. | Nplate (Biological) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Hematology | ||||||
| 01/09/2020 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $11.98 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.77 | General |
| 06/27/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Hematology / Oncology | ||||||
| 06/20/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $23.00 | General |
| 05/02/2019 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Hematology / Oncology | ||||||
| 04/11/2019 | Emmaus Medical, Inc. | Endari (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Sickle Cell | ||||||
| 03/07/2019 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Hematology | ||||||
| 02/07/2019 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: Hematology | ||||||
| 01/17/2019 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Oncology | ||||||
| 01/03/2019 | Spectrum Pharmaceuticals Inc. | Folotyn (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PAT | NOVARTIS PHARMACEUTICALS CORPORATION | $69,510 | 1 |
| A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea /Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises | Novartis Pharmaceuticals Corporation | $59,370 | 3 |
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PATIENTS WITH VASO-OCCLUSIVE CRISES | Novartis Pharmaceuticals Corporation | $16,455 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA /HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PAT | Novartis Pharmaceuticals Corporation | $1,520 | 1 |
About Cage Johnson
Cage Johnson is a Internal Medicine healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1609913417.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Cage Johnson has received a total of $153,154 in payments from pharmaceutical and medical device companies, with $15,180 received in 2024. These payments were reported across 37 transactions from 11 companies. The most common payment nature is "" ($146,855).
Ad
Practice Information
- Specialty Internal Medicine
- Location Los Angeles, CA
- Active Since 01/31/2007
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1609913417
Products in Payments
- ADAKVEO (Biological) $87,502
- ADAKVEO (Drug) $59,370
- OXBRYTA (Drug) $4,256
- Nplate (Biological) $110.88
- Kyprolis (Biological) $70.04
- JADENU (Drug) $34.56
- Revlimid (Drug) $23.60
- Folotyn (Drug) $22.05
- INREBIC (Drug) $22.00
- JAKAFI (Drug) $20.32
- Pomalyst (Drug) $19.26
- Aliqopa (Drug) $14.85
- XARELTO (Drug) $14.21
- Endari (Drug) $13.15
- PROMACTA (Drug) $11.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Los Angeles
Dr. Thomas Magee, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Julio Gutierrez, Md, MD
Internal Medicine — Payments: $920,439
Internal Medicine $920,439
Dr. Mohammad Kamgar, M.d, M.D
Internal Medicine — Payments: $471,176
Internal Medicine $471,176
Dr. Caroline Piatek, M.d,, M.D,
Internal Medicine — Payments: $468,526
Internal Medicine $468,526
Gottfried Konecny, Md, MD
Internal Medicine — Payments: $399,651
Internal Medicine $399,651
Dr. Elizabeth Volkmann, Md, MD
Internal Medicine — Payments: $397,666
Internal Medicine $397,666